US4877599A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Detection of vascular disease with labelled antibodies
Assignee: Beth Israel Deaconess Medical Center
•
Filing: 1988-07-11
•
Granted: 1989-10-31
•
Expires: 2008-07-11
Abstract
Abstract Vascular diseases including asymptomatic atherosclerosis can be diagnosed by administering a conjugate diagnostic reagent to a patient and then detecting the location and concentration of the conjugate reagent within the patient's vascular system. The conjugate reagents have a target-seeking, biologically active molecule as one component and a labeling means capable of extracorporeal detection as the other component. The biologically active molecules (BAMs) are chosen to have affinity for structural elements of the arterial wall which are either not present in the normal wall but are found in atherosclerotic or arteritic lesions, or which are not available to the blood-borne reagent within normal arterial walls, but are exposed to the reagent in atherosclerotic or arteriotic lesions.
Inventors
- 👤 Robert S. Lees
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 16:07
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/06; A61K49/08; A61K49/10; A61K49/14; A61K49/16; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1018; A61K2123/00
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
68 words
A conjugated diagnostic reagent having an antibody or fragment thereof with specific affinity for at least one arterial wall component associated with an abnormality of the vascular system, said arterial component being selected from the group consisting of insoluble, cross-linked elastin and insoluble, cross-linked fragments thereof and chondroitin sulfate proteoglycan compounds, a labeling means for labeling said antibody or fragment thereof, and not including porphyrin or derivatives thereof.
Claim 2
Dependent Claim
68 words
A conjugated diagnostic reagent having an antibody or fragment thereof with specific affinity for at least one arterial wall component associated with an abnormality of the vascular system, said arterial component being selected from the group consisting of insoluble, cross-linked elastin and insoluble, cross-linked fragments thereof and chondroitin sulfate proteoglycan compounds, a labeling means for labeling said antibody or fragment thereof, and not including porphyrin or derivatives thereof.
Claim 3
Dependent Claim
25 words
The conjugated reagent of claim 1 wherein said antibody or fragment thereof has a specific affinity for insoluble cross-linked elastin and insoluble, cross-linked fragments thereof.
Claim 4
Dependent Claim
19 words
The conjugated reagent of claim 1 wherein said antibody or fragment thereof has an affinity for chondroitin sulfate proteoglycan.
Claim 5
Dependent Claim
13 words
The conjugated reagent of claim 1 where the labeling means is a radionuclide.
Claim 6
Dependent Claim
30 words
The conjugated reagent of claim 4 where the radionuclide is selected from the group of Co-57, Cu-67, Ga-67, Ga-68, Ru-97, Tc-99m, In-111, In-113m, I-123, I-125, I-131, Hg-197, Au-198, and Pb-203.
Claim 7
Dependent Claim
24 words
The conjugated reagent of claim 1 wherein the labeling means is a magnetic contrast agent capable of being detected by magnetic resonance imaging techniques.
Claim 8
Dependent Claim
24 words
The conjugated reagent of claim 6 wherein the magnetic contrast agent is selected from the group of gadolinium, copper, cobalt, nickel and manganese complexes.
Claim 9
Dependent Claim
27 words
The conjugated reagent of claim 1 in which said antibody or fragment thereof is selected from the group consisting of a polyclonal antibody and a monoclonal antibody.
Claim 10
Dependent Claim
12 words
The conjugated reagent of claim 8 wherein said fragments are Fab fragments.
Claim 11
Independent Claim
156 words
A method for the detection of diseases of the vascular system including a symptomatic atherosclerosis, the method comprising: (a) preparing a conjugate of an antibody or fragment thereof having an affinity for at least one arterial wall component being selected from the group consisting of insoluble, cross-linked elastin and insoluble, cross-linked fragments thereof, and chondroitin sulfate proteoglycans, and a labeling means for labeling said antibody or fragment thereof, said conjugate not including porphyrin or derivatives thereof, said labeling means being linked to said antibody or fragment thereof and capable of being detected extracorporeally; (b) introducing the conjugate into the vascular system via a physiologically compatible vehicle in an amount effective for detection; (c) detecting the location of the conjugate within the vascular wall with an extracorporeal detection means capable of detecting the labeling means; and (d) quantifying the conjugate concentration at at least one location in order to determine the presence and extent of vascular disease.
Claim 12
Independent Claim
156 words
A method for the detection of diseases of the vascular system including a symptomatic atherosclerosis, the method comprising: (a) preparing a conjugate of an antibody or fragment thereof having an affinity for at least one arterial wall component being selected from the group consisting of insoluble, cross-linked elastin and insoluble, cross-linked fragments thereof, and chondroitin sulfate proteoglycans, and a labeling means for labeling said antibody or fragment thereof, said conjugate not including porphyrin or derivatives thereof, said labeling means being linked to said antibody or fragment thereof and capable of being detected extracorporeally; (b) introducing the conjugate into the vascular system via a physiologically compatible vehicle in an amount effective for detection; (c) detecting the location of the conjugate within the vascular wall with an extracorporeal detection means capable of detecting the labeling means; and (d) quantifying the conjugate concentration at at least one location in order to determine the presence and extent of vascular disease.
Claim 13
Dependent Claim
33 words
The method of claim 10 wherein the step of preparing a conjugate further includes employing an antibody or fragment thereof having a specific affinity for insoluble, cross-linked elastin and insoluble, cross-linked fragments thereof.
Claim 14
Dependent Claim
27 words
The method of claim 10 wherein the step of preparing a conjugate further includes employing an antibody or fragment thereof having an affinity for chondroitin sulfate proteoglycan.
Claim 15
Dependent Claim
41 words
The method of claim 10 wherein the step of preparing a conjugate further includes employing a radionuclide selected from the group of Co-57, Cu-67, Ga-67, Ga-68, Ru-97, Tc-99m, In-111, In-113m, I-123, I-125, I-131, Hg-197, Au-198 and Pb-203 as the labeling means.
Claim 16
Dependent Claim
22 words
The method of claim 10 wherein the step of preparing a conjugate further includes employing a monoclonal antibody or active fragment thereof.
Claim 17
Dependent Claim
22 words
The method of claim 10 wherein the step of preparing a conjugate further includes employing a polyclonal antibody or active fragment thereof.
Claim 18
Dependent Claim
44 words
The method of claim 10 wherein the step of preparing a conjugate further includes employing a radionuclide as the labeling means and the step of detecting the location of the conjugate within the vascular wall further includes detecting radiation therefrom with a radiation detector.
Claim 19
Dependent Claim
35 words
The method of claim 16 wherein the step of detecting radiation further includes employing a gamma camera to detect and make an image of gamma radiation emitted by the labeling means of the conjugate reagent.
References Cited (Backward Citations)
US4116776A
Cited
US4359453A
Cited
US4323546A
Cited
US4311688A
Cited
US4478815A
Cited
US4331647A
Cited
US4348376A
Cited
US4451570A
Cited
US4427371A
Cited
US4681782A
Cited
US4529694A
Cited
US4443427A
Cited
US4577636A
Cited
US4605413A
Cited
EP0137457A2
Cited
EP0163041A1
Cited
US4647445A
Cited
US4675287A
Cited
EP0189688A2
Cited
US4660563A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-10-30 | 1993-05-01 | 1993-10-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-10-30 | 1997-05-01 | 1997-10-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-10-30 | 2001-05-01 | 2001-10-31 | $7700.00 | Window Closed / Lapsed |